So Gilead has some good results on two trials of severely ill covid patients. Setting aside for the time being that Leronlimab will likely have better results for severely ill covid patients, here is what I am thinking about this morning: on Monday's conference call, NP made it clear that his focus was on quickly completing enrollment in the mild to moderate trial, not so much on completing enrollment in the severely ill trial. Very interesting!! NP must know that the mild to moderate patient trial provides much lower hanging fruit for Cytodyn than does the severely ill patient trial. And then these Gilead results won't even be discussed in the same sentence as Leronlimab. Very smart!!